Literature DB >> 25448878

The mitochondrial voltage-dependent anion channel 1 in tumor cells.

Varda Shoshan-Barmatz1, Danya Ben-Hail2, Lee Admoni2, Yakov Krelin2, Shambhoo Sharan Tripathi2.   

Abstract

VDAC1 is found at the crossroads of metabolic and survival pathways. VDAC1 controls metabolic cross-talk between mitochondria and the rest of the cell by allowing the influx and efflux of metabolites, ions, nucleotides, Ca2+ and more. The location of VDAC1 at the outer mitochondrial membrane also enables its interaction with proteins that mediate and regulate the integration of mitochondrial functions with cellular activities. As a transporter of metabolites, VDAC1 contributes to the metabolic phenotype of cancer cells. Indeed, this protein is over-expressed in many cancer types, and silencing of VDAC1 expression induces an inhibition of tumor development. At the same time, along with regulating cellular energy production and metabolism, VDAC1 is involved in the process of mitochondria-mediated apoptosis by mediating the release of apoptotic proteins and interacting with anti-apoptotic proteins. The engagement of VDAC1 in the release of apoptotic proteins located in the inter-membranal space involves VDAC1 oligomerization that mediates the release of cytochrome c and AIF to the cytosol, subsequently leading to apoptotic cell death. Apoptosis can also be regulated by VDAC1, serving as an anchor point for mitochondria-interacting proteins, such as hexokinase (HK), Bcl2 and Bcl-xL, some of which are also highly expressed in many cancers. By binding to VDAC1, HK provides both a metabolic benefit and apoptosis-suppressive capacity that offer the cell a proliferative advantage and increase its resistance to chemotherapy. Thus, these and other functions point to VDAC1 as an excellent target for impairing the re-programed metabolism of cancer cells and their ability to evade apoptosis. Here, we review current evidence pointing to the function of VDAC1 in cell life and death, and highlight these functions in relation to both cancer development and therapy. In addressing the recently solved 3D structures of VDAC1, this review will point to structure-function relationships of VDAC as critical for deciphering how this channel can perform such a variety of roles, all of which are important for cell life and death. Finally, this review will also provide insight into VDAC function in Ca2+ homeostasis, protection against oxidative stress, regulation of apoptosis and involvement in several diseases, as well as its role in the action of different drugs. We will discuss the use of VDAC1-based strategies to attack the altered metabolism and apoptosis of cancer cells. These strategies include specific siRNA able to impair energy and metabolic homeostasis, leading to arrested cancer cell growth and tumor development, as well VDAC1-based peptides that interact with anti-apoptotic proteins to induce apoptosis, thereby overcoming the resistance of cancer cell to chemotherapy. Finally, small molecules targeting VDAC1 can induce apoptosis. VDAC1 can thus be considered as standing at the crossroads between mitochondrial metabolite transport and apoptosis and hence represents an emerging cancer drug target. This article is part of a Special Issue entitled: Membrane channels and transporters in cancers.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Apoptosis; Cancer; Metabolism; Mitochondria; VDAC1

Mesh:

Substances:

Year:  2014        PMID: 25448878     DOI: 10.1016/j.bbamem.2014.10.040

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  83 in total

1.  VDAC1 in the diseased myocardium and the effect of VDAC1-interacting compound on atrial fibrosis induced by hyperaldosteronism.

Authors:  Hadar Klapper-Goldstein; Ankit Verma; Sigal Elyagon; Roni Gillis; Michael Murninkas; Srinivas Pittala; Avijit Paul; Varda Shoshan-Barmatz; Yoram Etzion
Journal:  Sci Rep       Date:  2020-12-16       Impact factor: 4.379

2.  Novel Compounds Targeting the Mitochondrial Protein VDAC1 Inhibit Apoptosis and Protect against Mitochondrial Dysfunction.

Authors:  Danya Ben-Hail; Racheli Begas-Shvartz; Moran Shalev; Anna Shteinfer-Kuzmine; Arie Gruzman; Simona Reina; Vito De Pinto; Varda Shoshan-Barmatz
Journal:  J Biol Chem       Date:  2016-10-13       Impact factor: 5.157

Review 3.  Revisiting trends on mitochondrial mega-channels for the import of proteins and nucleic acids.

Authors:  María Luisa Campo; Pablo M Peixoto; Sonia Martínez-Caballero
Journal:  J Bioenerg Biomembr       Date:  2016-05-05       Impact factor: 2.945

4.  Identifying Urinary and Serum Exosome Biomarkers for Radiation Exposure Using a Data Dependent Acquisition and SWATH-MS Combined Workflow.

Authors:  Shilpa Kulkarni; Antonius Koller; Kartik M Mani; Ruofeng Wen; Alan Alfieri; Subhrajit Saha; Jian Wang; Purvi Patel; Nuno Bandeira; Chandan Guha; Emily I Chen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-06-18       Impact factor: 7.038

5.  Repeated exposure of epithelial cells to apoptotic cells induces the specific selection of an adaptive phenotype: Implications for tumorigenesis.

Authors:  Lanfei Feng; Snezana Vujicic; Michael E Dietrich; Natalia Litbarg; Suman Setty; Angelika Antoni; Joyce Rauch; Jerrold S Levine
Journal:  J Biol Chem       Date:  2018-05-16       Impact factor: 5.157

6.  PGC1α and VDAC1 expression in endometrial cancer.

Authors:  Ofra Castro Wersäll; Lina Löfstedt; Igor Govorov; Miriam Mints; Marike Gabrielson; Maria Shoshan
Journal:  Mol Clin Oncol       Date:  2020-12-30

7.  Identification of potential predictive markers of dexamethasone resistance in childhood acute lymphoblastic leukemia.

Authors:  Nasrin Dehghan-Nayeri; Mostafa Rezaei-Tavirani; Mir Davood Omrani; Ahmad Gharehbaghian; Kourosh Goudarzi Pour; Peyman Eshghi
Journal:  J Cell Commun Signal       Date:  2016-10-24       Impact factor: 5.782

8.  Induction of autophagy by valproic acid enhanced lymphoma cell chemosensitivity through HDAC-independent and IP3-mediated PRKAA activation.

Authors:  Meng-Meng Ji; Li Wang; Qin Zhan; Wen Xue; Yan Zhao; Xia Zhao; Peng-Peng Xu; Yang Shen; Han Liu; Anne Janin; Shu Cheng; Wei-Li Zhao
Journal:  Autophagy       Date:  2015       Impact factor: 16.016

9.  The mitochondrion interfering compound NPC-26 exerts potent anti-pancreatic cancer cell activity in vitro and in vivo.

Authors:  Yang-Yang Dong; Yi-Huang Zhuang; Wen-Jie Cai; Yan Liu; Wen-Bing Zou
Journal:  Tumour Biol       Date:  2016-09-22

10.  Quinidine partially blocks mitochondrial voltage-dependent anion channel (VDAC).

Authors:  Chetan Malik; Subhendu Ghosh
Journal:  Eur Biophys J       Date:  2020-03-09       Impact factor: 1.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.